Fig. 5: The amyloid-β (Aβ) neuropathological signatures of future cognitive decline and external validation. | Communications Medicine

Fig. 5: The amyloid-β (Aβ) neuropathological signatures of future cognitive decline and external validation.

From: Integrating individualized connectome with amyloid pathology improves predictive modeling of future cognitive decline

Fig. 5

a Regions of interest (ROIs) whose regional Aβ standardized uptake value ratio (SUVR) measures were identified as features of future cognitive decline. This pattern of pathology signature was derived from the internal CogRes/RANN dataset. In external validation, features within the same ROIs pattern of ADNI participants were used to predict cognitive decline in dMemory, and subsequently compared to the actual decline score. The predicted cognitive change significantly correlated with the actual score (Pearson correlation; two-sided), and the relationship is significantly higher than the results obtained by random ROI selection (Randomization test; one-sided), demonstrating regional specificity. b Results of Aβ neuropathological signatures using connectivity-weighted network-based Aβ pathology (NAP) measures. c Results of Aβ neuropathological signatures using centrality-scaled NAP measures. The color indicates the network label of each ROI based on the Schaefer atlas. The analysis included seventy-two participants for whom all data were available. Cont: cognitive control network, DorsAttn: dorsal attention network, VisCent: visual central network, VisPeri: visual peripheral network, SalVentAttn: salience/ventral attention network, Default: default mode network.

Back to article page